Rx Enforcement In 2025: Shift Away From Opioid Makers But Tougher Approach On Ad/Promo

 
• By Sue Sutter
  
2025 Pink Sheet Perspectives
DTC ads and compounded drugs could end up on opposite ends of the FDA enforcement pendulum. (Shutterstock)

More from Compliance

More from Manufacturing